Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melatonin and human cancer.
Dogliotti L, Berruti A, Buniva T, Torta M, Bottini A, Tampellini M, Terzolo M, Faggiuolo R, Angeli A. Dogliotti L, et al. Among authors: bottini a. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):983-7. doi: 10.1016/0960-0760(90)90454-s. J Steroid Biochem Mol Biol. 1990. PMID: 2285610
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D. Dogliotti L, et al. Among authors: bottini a. J Clin Oncol. 1996 Apr;14(4):1165-72. doi: 10.1200/JCO.1996.14.4.1165. J Clin Oncol. 1996. PMID: 8648371 Clinical Trial.
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L. Bottini A, et al. Endocr Relat Cancer. 2005 Jun;12(2):383-92. doi: 10.1677/erc.1.00945. Endocr Relat Cancer. 2005. PMID: 15947110 Clinical Trial.
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Generali D, et al. Among authors: bottini a. Br J Cancer. 2008 Jun 3;98(11):1753-8. doi: 10.1038/sj.bjc.6604390. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506177 Free PMC article. Clinical Trial.
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG, Manzin E, Durando A, Defabiani E, De Matteis A, Ardine M, Castiglione F, Danese S, Bertone E, Alabiso O, Massobrio M, Dogliotti L. Tampellini M, et al. Among authors: bottini a. Breast Cancer Res Treat. 2006 Aug;98(3):241-8. doi: 10.1007/s10549-005-9155-y. Epub 2006 May 3. Breast Cancer Res Treat. 2006. PMID: 16670941
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A. Generali D, et al. Among authors: bottini a. Bone. 2007 Jan;40(1):182-8. doi: 10.1016/j.bone.2006.06.023. Epub 2006 Aug 24. Bone. 2007. PMID: 16935041
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
Tampellini M, Berruti A, Gorzegno G, Bitossi R, Bottini A, Durando A, De Matteis A, Farris A, Donadio M, De Fabiani E, Manzin E, Arese P, Sarobba MG, Castiglione F, Moro G, Bonazzi G, Nuzzo F, Massobrio M, Dogliotti L. Tampellini M, et al. Among authors: bottini a. Tumour Biol. 2001 Nov-Dec;22(6):367-73. doi: 10.1159/000050639. Tumour Biol. 2001. PMID: 11786730
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Mele T, et al. Among authors: bottini a. Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3. Breast Cancer Res Treat. 2010. PMID: 20680681 Clinical Trial.
175 results